Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally

Journal of Gene Medicine

Volumn 11, Issue 8, 2009, Pages 718-728

  Fewell, Jason G ^a   Matar, Majed ^a   Rice, Jennifer S ^a   Brunhoeber, Elaine ^a   Slobodkin, Gregory ^a   Pence, Casey ^a   Worker, Miranda ^a   Lewis, Danny H ^a   Anwer, Khursheed ^a  

^a EGEN Inc   (United States)

Author keywords

Gene therapy; Interleukin 12; Nonviral; Ovarian cancer; PEI; Polymer

Indexed keywords

CARBOPLATIN; GAMMA INTERFERON; INTERLEUKIN 12; PACLITAXEL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES FLUID; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE THERAPY; HUMAN; LEUKOCYTE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIDE EFFECT; SPLEEN WEIGHT; SURVIVAL TIME; THROMBOCYTE; UPREGULATION; ZETA POTENTIAL;

ANIMALS; ASCITES; BLOOD CELL COUNT; BODY WEIGHT; CARBOPLATIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR BURDEN; VIRUSES;

MURINAE; MUS;

EID: 70349511935     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1356     Document Type: Article

References (50)

1. American Cancer Society. Cancer Facts and Figures 2008. American Cancer Society: Atlanta, GA, 2008.
2. Hasenburg A, Tong XW, Rojas-Martinez A, et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000; 7: 839-844.
3. Bast RC, Yu Y, Xu FJ, Le XF, Mills GB. Molecular approaches to management of epithelial ovarian cancer. Int J Gynecol Cancer 2000; 10: 2-7.
4. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 2007; 7: 1705-1721.
5. Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biotechnol J 2006; 1: 138-147.
6. Li CY, Huang Q, Kung HF. Cytokine and immuno-gene therapy for solid tumors. Cell Mol Immunol 2005; 2: 81-91.
7. Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996; 1: 88-97.
8. Oshikawa K, Rakhmilevich AL, Shi F, Sondel PM, Yang N, Mahvi DM, 2001. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer. Hum Gene Ther 2001; 12: 149-160.
9. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586.
10. Freedman RS, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum M, Platsoucas CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther 1998; 4: 121-140.
11. Lenzi R, Edwards R, June C, et al. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 2007; 5: 66.
12. Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389-1397.
13. van Herpen CM, Looman M, Zonneveld M, et al. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 2004; 10: 2626-2635.
14. Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003; 21: 2564-2573.
15. Lenzi R, Rosenblum M, Verschraegen C, et al. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 2002; 8: 3686-3695.
16. Motzer RJ, Rakhit A, Thompson JA, et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001; 21: 257-263.
17. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902-908.
18. Salem ML, Gillanders WE, Kadima AN, et al. Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res 2006; 26: 593-608.
19. Imboden M, Shi F, Pugh TD, et al. Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study. Hum Gene Ther 2003; 14: 1037-1048.
20. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153: 1697-1706.
21. Tan J, Newton CA, Djeu JY, et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 1996; 56: 3399-3403.
22. Quezada A, Larson J, French M, et al. Biodistribution and safety studies of hDEL-1 plasmid based gene therapy in mice and rabbit models. J Pharm Pharmacol 2004; 56: 177-185.
23. Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther 2000; 2: 302-317.
24. Mahato RI, Lee M, Han S, Maheshwari A, Kim SW. Intratumoral delivery of p2CMVmIL-12 using water soluble lipopolymers. Mol Ther] 2000; 4: 130-138.
25. Anwer K, Rhee BG, Mendiratta SK. Recent progress in polymeric gene delivery systems. Crit Rev Ther Drug Carrier Syst 2003; 20: 249-293.
26. Fewell JG, Matar M, Slobodkin G, et al. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. J Control Release 2005; 109: 288-298.
27. Janát-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim SW. Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer. Anticancer Res 2006; 26: 3223-3228.
28. Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 4: 585-591.
29. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162-176.
30. Bracci L, Proietti E, Belardelli F. IFN-alpha and novel strategies of combination therapy for cancer. Ann NY Acad Sci 2007; 1112: 256-268.
31. Hurwitz H, Kabbinavar F. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 2005; 69(Suppl 3): 17-24.
32. Mendiratta SK, Quezada A, Matar M, et al. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma. Human Gene Ther 2000; 11: 1851-1862.
33. Zagozdzon R, Go3ab J, Stok3osa T, et al. Effective chemoimmunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer 1998; 77: 720-727.
34. Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Clin Cancer Res 1997; 3: 1661-1667.
35. Leonard JP, Sherman ML, Fisher GL, et al. Effects of Single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon production. Blood 1997; 90: 2541-2548.
36. Sonawane ND, Szoka FC Jr, Verkman AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 2003; 278: 44826-44831.
37. Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep 2005; 13: 1153-1158.
38. Bozkurt N, Yuce K, Basaran M, Gariboglu S, Kose F, Ayhan A. Correlation of serum and ascitic IL-12 levels with secondlook laparotomy results and disease progression in advanced epithelial ovarian cancer patients. Int J Gynecol Cancer 2006; 16: 83-86.
39. Ichim CV, 2005. Revisiting immunosurveillance and immunostimuation: Implications for cancer immunotherapy. J Transl Res 2005; 3: 8.
40. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153: 1249-1256.
41. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995; 55: 360-368.
42. Duda DG, Sunamura M, Lozonschi L, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenic effects of interleukin 12. Cancer Res 2000; 60: 1111-1116.
43. Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Nat Cancer Inst 2002; 94: 762-768.
44. Schumacher JJ, Dings RP, Cosin J, Subramanian IV, Auersperg N, Ramakrishnan S. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res 2007; 67: 3683-3690.
45. Anwer K, Meaney C, Kao G, Hussain N, Shelvin R, Earls RM. Cationic lipid-based delivery system for systemic cancer gene therapy. Cancer Gene Ther 2000; 7: 1156-1164.
46. Louis MH, Dutoit S, Denoux Y, Erbacher P, Deslandes E, Behr JP. Intraperitoneal linear polyethylenimine (L-PEI)mediated gene delivery to ovarian carcinoma nodes in mice. Cancer Gene Ther 2006; 13: 367-374.
47. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999; 162: 6811-6818.
48. Mullins DW, Koci MD, Burger CJ, Elgert KD. Interleukin12 overcomes paclitaxel-mediated suppression of T-cell proliferation. Immunopharmacol Immunotoxicol 1998; 20: 473-492.
49. Pressley JS, Elgert KD. Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: combination therapy using paclitaxel and IL-12. Cancer Invest 2006; 24: 351-359.
50. Anwer K, Barnes MN, Anderson ML, et al. Progress in the clinical development of a novel IL-12 gene therapeutic for the treatment of recurrent ovarian cancer. Mol Ther 2007; 15: S69.